

November 2021

## **Ozempic from Novo Nordisk's use within the Belfast City Hospital Diabetic Clinic**

### **Total number of patients prescribed Ozempic by the Belfast City Diabetic Clinic by age**

There is no electronic mechanism to identify the total number of patients prescribed Ozempic by the Belfast City Hospital Diabetic Clinic by age. The only way this can be done is to do an audit of all patient's case notes. This cannot be completed within 18 hours.

Section 12 of the FOI Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more person spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

**Total number of patients that flagged having problems with the drug**  
**Problems cited by patients with drug by age group**  
**Total number of patients hospitalised after using the drug**  
**Total number of patient who were deceased within 1 month of using the drug**  
**Cause of death**

Belfast Trust uses two mechanisms to record information about serious adverse drug reactions. This will include those patients who require hospitalisation, and or those patients who died as a result of an adverse reaction to a drug.

We carried out a search to compile an adverse drug reaction report using \*Ozempic\* in the text search fields on our Datix database but no records were returned.

The second mechanisms is the UK Yellow Card Scheme for adverse drug reactions. The MHRA runs the Yellow Card Scheme which collects and monitors information on suspected safety concerns on medicines and vaccines. This scheme relies on voluntary reporting of suspected safety concerns by Healthcare Professionals or Members of Public. Staff record on the patients' case notes if they have reported any concerns to the Yellow card Scheme. Belfast Trust does not collect information about the number of safety concerns reported to the Yellow Card Scheme. Any specific information requests should be directed to e-mail: [yellowcard@mhra.gov.uk](mailto:yellowcard@mhra.gov.uk)